The latest edition of the Drug Discovery TOE profiles emerging technology platforms, strategic business models and initiatives, breakthrough approvals and trials for drug discovery and development. The role and impact of emerging technology such as artificial intelligence in drug discovery has also been discussed. This TOE issue profiles innovations at the academia research setting, drugs that have received regulatory approval, drug discovery initiatives, and strategies by top pharmaceutical companies.
The Drug Discovery TechVision Opportunity Engine (TOE) reports and analyzes about the latest developments in drug discovery and therapeutics, thereby providing an opportunity to acquire strategic insights into crucial developments in this industry domain. Technologies profiled include those used for biomarker and target discovery such as high throughput screening, signal transduction, micro array, RNAi, metabolomics, toxicogenomics, biosensors and nanotechnology. In addition to these, a fair focus shall be dedicated to the latest trends in therapeutic approaches across a diversity of diseases including infectious, genetic, metabolic, neurological, cardiac, and autoimmune disorders.
The Health and Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare.
Keywords: Orphan designation, IgA nephropathy, induced pluripotent cells, cloud technology, artificial intelligence, public private partnerships, drug discovery, open innovations, fast track initiative, lead optimization, early stage drug discovery, seeding drug discovery initiative